Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 237

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 237
---
 HOLDINGS, INC.

(f/k/a Bellevue Life Sciences Acquisition Corp.)

CONSOLIDATED STATEMENTS
OF CHANGES IN STOCKHOLDERS’ DEFICIT

FOR THE YEARS ENDED
DECEMBER 31, 2024 AND 2023

    Additional  
       
    Total 

    Common Stock  
    Paid-in  
    Accumulated  
    Stockholders’ 

    Shares  
    Amount  
    Capital  
    Deficit  
    Deficit 
  
    Balance, December 31, 2022 
     1,725,000  
    $173  
    $24,827  
    $(62,508) 
    $(37,508)
  
    Sale of 430,000 Private Placement Units 
     430,000  
     43  
     4,299,957  
     -  
     4,300,000 
  
    Fair value of warrants and rights included in the Units sold in the Initial Public Offering and in the exercise of the over-allotment 
     -  
     -  
     1,236,527  
     -  
     1,236,527 
  
    Accretion of common stock to redemption value 
     -  
     -  
     (5,561,311) 
     (3,888,323) 
     (9,449,634)
  
    Excise tax payable attributable to redemption of common stock 
     -  
     -  
     -  
     (359,957) 
     (359,957)
  
    Net income 
     -  
     -  
     -  
     403,780  
     403,780 
  
    Balance, December 31, 2023 
     2,155,000  
    $216  
    $-  
    $(3,907,008) 
    $(3,906,792)
  
    Accretion of common stock to redemption value 
     -  
     -  
     -  
     (1,653,419) 
     (1,653,419)
  
    Excise tax payable attributable to redemption of common stock 
     -  
     -  
     -  
     (